drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous T lymphocytes genetically engineered to express a chimeric antigen receptor targeting carcinoembryonic antigen (CEA/CEACAM5), providing CD3ζ and costimulatory signaling to activate T cells and induce cytotoxicity against CEA-positive tumor cells.
nci_thesaurus_concept_id
C188356
nci_thesaurus_definition
A preparation of T-lymphocytes engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human carcinoembryonic antigen (CEA), with potential immunostimulating and antineoplastic activities. Upon administration, anti-CEA CAR T cells specifically recognize and induce selective toxicity in CEA-expressing tumor cells. CEA, a member of the CEA family of proteins, plays a key role in cell migration, cell invasion and cell adhesion, and is overexpressed by a variety of cancer types.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T lymphocytes engineered to express a chimeric antigen receptor targeting CEA/CEACAM5. CAR engagement on CEA-positive tumor cells delivers CD3ζ and costimulatory signaling, activating and expanding the T cells to release cytokines and kill targets via perforin/granzyme-mediated cytotoxicity.
drug_name
Anti-CEA CAR T cells
nct_id_drug_ref
NCT06013111